New urine test may spare bladder cancer patients from overtreatment
NCT ID NCT07252297
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at whether a test that checks for a specific gene marker (SIX6) in urine or tissue can predict if bladder cancer will come back after surgery. Researchers will compare SIX6 levels in 177 patients who had low-risk bladder cancer to see if the test can tell who is likely to have a recurrence. If it works, doctors could use this test to avoid giving extra treatments to patients who don't need them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SIX6 Gene Methylation Assay
What this could lead to
If successful, this test could help doctors better predict which bladder cancer patients are at risk of recurrence, allowing for more personalized treatment and fewer unnecessary therapies.
What could go wrong
This is a small, retrospective study, so results may not apply to all patients. The test is still experimental and needs larger trials to confirm its accuracy and usefulness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xi Jing Hopspital
Xi'an, ShannxI, 710300, China